- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
COPD Management Approaches With Dual Bronchodilator and Triple Therapies (Ernest N. Morial Convention Center - Exhibit Hall - Learning Theater 1) - Oct 23, 2019 - Abstract #CHEST2019CHEST_4589;
Discuss how symptoms and exacerbations may help guide COPD management by exploring appropriate COPD patient types for dual bronchodilator (LAMA/LABA) and triple therapy (ICS/LABA/LAMA) treatment options.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Learn about a nebulized long-acting muscarinic antagonist for the maintenance treatment of patients with COPD. (Ernest N. Morial Convention Center - Exhibit Hall - Learning Theater 1) - Oct 23, 2019 - Abstract #CHEST2019CHEST_4577;
Discuss how symptoms and exacerbations may help guide COPD management by exploring appropriate COPD patient types for dual bronchodilator (LAMA/LABA) and triple therapy (ICS/LABA/LAMA) treatment options. Discuss how symptoms and exacerbations may help guide COPD management by exploring appropriate COPD patient types for dual bronchodilator (LAMA/LABA) and triple therapy (ICS/LABA/LAMA) treatment options.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. (Pubmed Central) - Oct 20, 2019
Discuss how symptoms and exacerbations may help guide COPD management by exploring appropriate COPD patient types for dual bronchodilator (LAMA/LABA) and triple therapy (ICS/LABA/LAMA) treatment options. This study highlights the crucial role that lipids play in the independent development of both NAFLD and CKD and demonstrates the importance of lipid-lowering treatments in various metabolic diseases featured by lipid load, from the "rare" GSDIa to the "epidemic" morbid obesity or type 2 diabetes.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, Ocaliva (obeticholic acid) / Intercept, Lacromid (bezafibrate) / Remedica
ADDITIVE BENEFICIAL EFFECTS OF FIBRATES COMBINED WITH OBETICHOLIC ACID IN THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND INADEQUATE RESPONSE TO SECOND-LINE THERAPY (Hynes Convention Center, Hall B) - Oct 15, 2019 - Abstract #AASLD2019AASLD_3159;
Patients with PBC treated for at least 12 weeks with, and with no intolerance to, a combination of OCA (5-10 mg/d), fibrates (bezafibrate 400 mg/d or fenofibrate 200 mg/d) and UDCA (13-15 mg/kg/d) because of a Paris-2 inadequate response to one second-line option were included in a multicenter retrospective cohort study. Triple therapy with fibrates, OCA, and UDCA improves biochemical liver tests and increases the rate of ALP normalization in patients with PBC and incomplete response to second-line therapy.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Fibrate Therapy in Hemodialysis Patients: A Prospective 10-Year Study (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_3110;
Both drugs were well-tolerated and could be useful alternatives to statin in HD patients with hyperlipidemia. Funding Government Support - Non-U.S.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
AKI Associated with Fenofibrate (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_2329;
Conclusion Diabetes mellitus, hypertension, and concomitant use of RAS blocker have a statistically significant association with acute kidney injury by fenofibrate in our study. And patients with chronic kidney disease have greater risk in acute kidney injury by fenofibrate.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: Paradoxical fall in proteinuria during pregnancy in an LCAT-deficient patient-A case report. (Pubmed Central) - Oct 8, 2019
Her pregnancy was complicated by rising triglyceride levels from the second trimester requiring treatment with omega-3 fatty acid and fenofibrate...She was diagnosed with pre-eclampsia and had an emergency cesarean section at 39 weeks delivering a healthy baby. This case adds to the knowledge of the pathophysiology of LCAT deficiency during pregnancy and will be useful in future patient management.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Fibrates as Drugs with Senolytic and Autophagic Activity for Osteoarthritis Treatment (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3177;
These results demonstrate that FDA-approved fibrate drugs targeting lipid metabolism protect against cartilage degeneration with aging and OA. Thus, these drugs could have immediate clinically utility for the treatment of OA and age-related cartilage degeneration.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, Lacromid (bezafibrate) / Remedica
HUMAN-DERIVED HEPATIC IN VITRO MODELS IDENTIFY DISTINCT ANTI-NASH EFFICACIES OF PPAR-AGONISTS (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2005;
Elafibranor, followed by pioglitazone, showed the strongest anti-‘NASH’ activity in all in vitro systems tested. The effects were most firmly unveiled by PHH and stem cells and correspond to current clinical guidelines and patient trial results.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
ONLINE EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND COMPETENCE IN MANAGING COPD WITH DUAL BRONCHODILATOR AND TRIPLE COMBINATION THERAPIES (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 1) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3657;
Knowledge is limited regarding the differences between triple therapy (ICS/LABA/LAMA) and dual bronchodilator therapy for COPD practice. This study demonstrates the success of online, 2-faculty, video-based education in improving the knowledge and confidence of pulmonologists and PCPs regarding the use of triple therapy versus dual bronchodilation in COPD.Clinical Implications:Properly implemented, this type of intervention can translate into improvements in patient care and long-term outcomes.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
IS THAT A HIGH OR LOW BLOOD SUGAR I AM FEELING? HYPOGLYCEMIC DIABETIC KETOACIDOSIS (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3338;
This study demonstrates the success of online, 2-faculty, video-based education in improving the knowledge and confidence of pulmonologists and PCPs regarding the use of triple therapy versus dual bronchodilation in COPD.Clinical Implications:Properly implemented, this type of intervention can translate into improvements in patient care and long-term outcomes. He was discharged in stable condition with insulin and fenofibrate prescriptions the day after the presentation.DKA results from dehydration during a state of relative insulin deficiency, usually associated with high blood glucose and organic acid levels.The likely cause of hypoglycemia in this DKA patient may be starvation and home administration of a high dose of insulin...Hypoglycemic DKA, a paradoxical condition that requires prompt recognition and treatment.
- |||||||||| glycopyrrolate/indacaterol/mometasone (QVM149) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
TRENDS OF QUALITY OF COPD MANAGEMENT IN KOREA: 3-YEAR FOLLOW-UP OF NATIONAL HEALTH INSURANCE CLAIM DATA (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2681;
In conclusion, from the national data of quality assessment program, we showed that the prescription rate of inhaled bronchodilator was decreasing in patients who were regularly followed for COPD from 2014 to 2016 in Korea. And the performance rate of spirometry was still low.Clinical Implications:A new strategy needs to be developed to increase prescription rate of inhaled bronchodilator and performance rate of spirometry to improve quality of COPD management.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
EARLY THERAPEUTIC PLASMA EXCHANGE FOR TREATMENT OF RECURRENT TRIGLYCERIDE-INDUCED PANCREATITIS (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2594;
Currently, he is managed on fenofibrate 200 mg and rosuvastatin 20 mg daily.In light of this case and drawing from literature, we propose that early TPE not only bears clinical significance in treatment of TGIP, but can also reduce overall costs compared to conventional medical therapy and associated costs, especially in terms of length of stay. This highlights the need for larger-scale studies to compare TPE versus standard medical therapy with direct comparison of mortality, complications, hospital length-of-stay and cost-effectiveness.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Trial completion, Head-to-Head: ARGON: Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (clinicaltrials.gov) - Sep 20, 2019
P3, N=1436, Completed,
This highlights the need for larger-scale studies to compare TPE versus standard medical therapy with direct comparison of mortality, complications, hospital length-of-stay and cost-effectiveness. Active, not recruiting --> Completed
- |||||||||| Clinical, Journal: Linking microbial diversity and population dynamics to the removal efficiency of pharmaceutically active compounds (PhACs) in an anaerobic/anoxic/aerobic (AO) system. (Pubmed Central) - Sep 20, 2019
Biota-environment (BIO-ENV) analysis revealed strong correlations between population shifts of the activated sludge community and the REs of PhACs of the different pharmaceutical families. Increased REs of clarithromycin, furosemide, bezafibrate and gemfibrozil were concomitant to higher relative abundances of bacterial phylotypes classified within the Rhodobacteraceae and Sphingomonadaceae (Alphaproteobacteria), while those of Betaproteobacteria, Chloroflexi and Methanomethylovorans (Euryarchaea) correlated positively with the REs of up to seven PhACs belonging to different therapeutic groups.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: A Cell-Based Assay to Investigate Hypolipidemic Effects of Nonalcoholic Fatty Liver Disease Therapeutics. (Pubmed Central) - Sep 12, 2019
Our results indicate that hepatocytes fatten in a concentration- (0.75-1.5 mM of fatty acids) and time-dependent manner, with a substantial increase in intracellular lipid levels seen within 6 h. Additionally, a method to quantify lipid levels in cells using a fluorescent reagent that is more sensitive than that in conventional assays and adaptable for high-throughput screening is presented. Lastly, the utility of the in vitro cell model and an assay based on AdipoRed to measure hypolipidemic effects of therapeutic drugs is demonstrated using fenofibrate, a molecule that was previously shown to lower lipid levels in the liver.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. (Pubmed Central) - Sep 11, 2019
Lastly, the utility of the in vitro cell model and an assay based on AdipoRed to measure hypolipidemic effects of therapeutic drugs is demonstrated using fenofibrate, a molecule that was previously shown to lower lipid levels in the liver. We did not observe evidence for an association between extended-release niacin versus fenofibrate and rates of major gastrointestinal bleeding or intracranial hemorrhage.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, danazol oral / Generic Mfg.
Journal: Effect of surfactant-bile interactions on the solubility of hydrophobic drugs in biorelevant dissolution media. (Pubmed Central) - Sep 11, 2019
The large dependence of the drug solubility on surfactant-bile interactions (in which the drug molecules do not play a major role per se) highlights how the complex interplay between excipients and bile salts can change significantly one of the key parameters which govern the oral absorption of poorly water-soluble drugs, viz. the drug solubility in the intestinal fluids.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Fenofibrate improves vascular endothelial function in diabetic mice. (Pubmed Central) - Sep 6, 2019
In-vitro, fenofibrate treatment improved the impaired function of MAECs, increased nitric oxide production, and decreased the O- level, as well as activated eNOS and AMPK phosphorylation in cultured MAECs by high glucose. Fenofibrate could ameliorate endothelium-dependent vasodilation in diabetic mice and relieve high glucose-induced endothelial dysfunction, which was possibly related to the activation of eNOS and AMPK phosphorylation.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Review, Journal: Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy. (Pubmed Central) - Sep 6, 2019
We first show that TFC, OF, and OP secrete CXCL8 and CXCL10 differentially, sustained by specific proinflammatory cytokines or their combination. This could reflect a different role of the two chemokines in the course of the disease, as CXCL10 could be associated with the initial phase of the disease when IFNγ is preponderant, while CXCL8 could be associated with a later chronic phase of the disease, when TNFα prevails.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia. (Pubmed Central) - Aug 31, 2019
The positive effect of short-term fenofibrate treatments on vascular endothelial functions in patients with hypertriglyceridemia has been demonstrated by increasing the serum NO levels. Agents such as fenofibrate targeting PPARα-associated signaling pathways show promise as an alternative treatment of vascular dysfunction related to advanced age and hyperlipidemia.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Model design for screening effective Antihyperlipidemic drugs using zebrafish system. (Pubmed Central) - Aug 30, 2019
Intravascular cholesterol levels were significantly increased after HCD treatment and decreased after drug treated. The high-fat zebrafish model induced by HFD-fed was available and successful, besides, the Oil red O staining may be an available and rapid method for screening lipid-lowering drugs.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Trial completion: A Long-term Safety Study of QVM149 in Japanese Patients With Asthma (clinicaltrials.gov) - Aug 28, 2019
P3, N=96, Completed,
However, after digestion, these formulations still outperformed their crystalline counterparts. Active, not recruiting --> Completed
- |||||||||| Seebri (glycopyrronium bromide) / Novartis, Vectura, Sosei
Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study (6F) - Aug 26, 2019 - Abstract #ERS2019ERS_5632;
INTRODUCTION: Persistent airflow limitation (PAL) may predict a positive clinical response to add-on long-acting muscarinic antagonist (LAMA) in asthmatics on inhaled corticosteroids and long-acting β2-receptor agonists (ICS/LABA) OBJECTIVES: We evaluated the effect of extrafine HS beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) on asthma exacerbations in a subset of patients with PAL TRIGGER was a phase III randomized, parallel group trial comparing 52-week treatment with BDP/FF/GB 800/24/50 µg/d to BDP/FF 800/24 µg/d via pressurized metered dose inhalers (pMDI) and open-label treatment consisting of BDP/FF plus tiotropium Respimat® 5 μg/d (TioR) in adult patients with uncontrolled asthma on high-dose ICS/LABA and a history of exacerbation in the past year... PAL is associated with a greater response to triple therapy with extrafine HS BDP/FF/GB in patients with asthma uncontrolled on high dose ICS/LABA
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi, Avessa (formoterol / fluticasone) / Sun Pharma
A randomized cross-over study of user satisfaction with inhalant devices in asthma patients (TP-04) - Aug 26, 2019 - Abstract #ERS2019ERS_4224;
Factors influencing overall satisfaction were gender (p=0.020) and FFC (p=0.028). Conclusions Although both devices possessed high satisfaction, operability, and adherence to regime, FFC showed a higher satisfaction level in the elderly than VFC.
|
